Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crestor 10 mg Dose Is Initial Focus In Canadian Marketing Campaign

Executive Summary

AstraZeneca's marketing message for Crestor in Canada is focusing on the efficacy of the 10 mg dose

You may also be interested in...



AstraZeneca Crestor 10 mg Fixed Starting Dose Supported By Committee

Dosing for AstraZeneca's statin Crestor in the general population should start with a fixed dose of 10 mg, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended July 9

AstraZeneca Crestor 10 mg Fixed Starting Dose Supported By Committee

Dosing for AstraZeneca's statin Crestor in the general population should start with a fixed dose of 10 mg, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended July 9

AstraZeneca Crestor review

AstraZeneca's statin Crestor (rosuvastatin) will be reviewed July 9 by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for treatment of hypercholesterolemia and mixed dyslipidemia. In response to a May 2002 "approvable" letter, AstraZeneca submitted data on Feb. 12 on the 10 mg, 20 mg and 40 mg doses, giving the NDA a mid-August user fee goal (1"The Pink Sheet" May 5, p. 19). Development of an 80 mg dose was discontinued due to reports of rhabdomyolysis and renal impairment. The meeting will be held at the Holiday Inn in Bethesda, Md. at 8:30 a.m...

Related Content

UsernamePublicRestriction

Register

PS041730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel